Lenvatinib is an oral multitarget receptor tyrosine kinase inhibitor that is approved for the treatment of hepatocellular carcinoma (HCC) and metastatic renal cell carcinoma [49, 50]. Here, NTRK1 is linked to hepatocellular carcinoma.